Your ASCO checklist of news, reviews, interviews and yes, a scandal

ASCO

CHICAGO--The American Society of Clinical Oncology’s annual meeting is the biopharma version of Cannes or Sundance: A few days of non-stop premieres and news conferences, sideline interviews and sometimes, scandal. Want to keep track of this year’s ASCO data celebs and reviews? Here’s what you need to know so far.

  • Johnson & Johnson's multiple myeloma med Darzalex won FDA approval last year amid a flurry of green lights for new rival meds. But some new data could give it a marketing boost. The drug held off cancer progression and death in previously treated patients by 61% compared with the standard combo alone, according to Phase III study results that rolled out Sunday. Report
     
  • Bristol-Myers Squibb's checkpoint inhibitor Opdivo and older immunotherapy Yervoy already have FDA approval to attack melanoma with a one-two punch. Now, the duo have a new use in first-line lung cancer in their sights. Study data showed that 57% of lung cancer patients treated with the combo responded, and that’s more than double the 28% Opdivo had previously posted on its own. Story
     
  • Roche’s highly anticipated immunotherapy Tecentriq hit the scene just last month as a second-line therapy for bladder cancer--and bigger market in that disease could be on tap soon. In a Phase II study of patients ineligible for standard platinum-based chemo, 24% saw their tumors shrink--and that number went as high as 28% in patients with higher levels of PD-L1 expression. After 14.4 months of follow-up, 75% of responders still had seen no disease progression. News
     
  • Tecentriq’s advent is a good thing for Roche in light of some other ASCO news: Mylan’s copycat version of its longtime top-seller Herceptin matched the brand in safety and efficacy in treating advanced, HER2-positive breast cancer. That med delivered $6.5 billion to Roche’s top line last year, and Mylan is one of several biosim makers looking to take a piece of that pie. FiercePharma | FierceBiotech
     
  • AbbVie ($ABBV) got a chance Sunday to start explaining why it paid a whopping $5.8 billion up front--with $4 billion reserved for milestones--for Stemcentrx and its overnight cancer drug sensation Rova-T. The results are still preliminary, but investigators spotlighted results that showed 11 out of 60 (18%) evaluable patients treated with Rova-T (rovalpituzumab tesirine) experienced tumor shrinkage, and 41 (68%) achieved a clinical benefit, clearing the minimum bar for stable disease. The data wasn’t quite good enough to convince market-watchers that the Stemcentrx price was justified. Story
     
  • The top contenders wrestling for the spotlight reserved for breakout cancer drugs at ASCO this year share a common distinguishing factor: They’re designed to take a novel shot at a new target. And Ganymed Pharmaceuticals, a little-known German biotech backed by billionaire twins, rode that targeting trend straight to the center ring on Sunday. Article
     
  • Juno Therapeutics ($JUNO) and Kite Pharma ($KITE) have reiterated their ambition to bring CAR-T therapies to market in 2017 following the publication of fresh clinical trial data at ASCO. The stage is now nearly set for a flurry of regulatory filings and decisions over the next year or so as Juno, Kite and Novartis ($NVS) all race to get their CAR-T therapies in front of FDA. Report
     
  • As for scandal, Immunomedics was barred from its scheduled presentation after ASCO officials discovered that the company had sneaked in some previously presented data on its triple-negative breast cancer drug. That's a violation of the meeting's rules. Nowhere close to Hollywood scandal standards, but it sent the company's shares tumbling. Story
     

Related Articles:
How can patients get their money's worth from cancer meds? ASCO revamps 'value' tool to help decide
Merck's Keytruda shines in pre-ASCO abstract release, with Pfizer catching the limelight, too
Roche's Tecentriq bursts onto immuno-oncology scene, with Merck and BMS in its sights
Looking to build Darzalex a bigger market, J&J teams up with Roche for atezo combo trials
BMS' Opdivo produces 5-year survival rate for a third of advanced melanoma patients
Roche looks ahead to immuno-oncology, MS to back up big-selling cancer meds

Read more on

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.